Bacteriophages and Their Immunological Applications against Infectious Threats

Journal of Immunology Research

Volumn 2017, Issue , 2017, Pages

  Criscuolo, Elena ^a   Spadini, Sara ^a,b   Lamanna, Jacopo ^a,b   Ferro, Mattia ^a,b   Burioni, Roberto ^a,b  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ENDOLYSIN; HOLIN; MONOCLONAL ANTIBODY; POLYSACCHARIDE DEPOLYMERASE; UNCLASSIFIED DRUG; VACCINE; VIRION ASSOCIATED PEPTIDOGLYCAN HYDROLASE; VIRAL PROTEIN;

ANTIBODY DETECTION; BACTERIOPHAGE; BIOSENSOR; HUMAN; INFECTION; MICROORGANISM DETECTION; MULTICENTER STUDY (TOPIC); NONHUMAN; PHAGE DISPLAY; PHAGE THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; BACTERIAL INFECTION; BIOLOGICAL THERAPY; CELL SURFACE DISPLAY; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; MICROBIOLOGY; MOUSE; PHYSIOLOGY; PROCEDURES;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; BACTERIAL INFECTIONS; BACTERIOPHAGES; BIOLOGICAL THERAPY; CELL SURFACE DISPLAY TECHNIQUES; CLINICAL TRIALS AS TOPIC; HUMANS; MICE; PHAGE THERAPY; VIRAL PROTEINS;

EID: 85018941482     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2017/3780697     Document Type: Review

References (140)

1. K. E. Wommack, R. T. Hill, M. Kessel, E. Russek-Cohen, and R. R. Colwell, "Distribution of viruses in the Chesapeake Bay," Applied and Environmental Microbiology, vol. 58, no. 9, pp. 2965-2970, 1992.
2. F. D'Herelle, F. W. Twort, J. Bordet, and A. Gratia, "Discussion on the bacteriophage (bacteriolysin)," BMJ, vol. 2, pp. 289-299, 1922.
3. F. Twort, "The discovery of the 'bacteriophage'," The Lancet, vol. 205, no. 5303, p. 845, 1925.
4. D. H. Duckworth, "Who discovered bacteriophage?" Bacteriological Reviews, vol. 40, no. 4, pp. 793-802, 1976.
5. S. Giguère, J. F. Prescott, and P. M. Dowling, Antimicrobial Therapy in Veterinary Medicine, John Wiley & Sons, Hoboken, NJ, USA, 2013.
6. K. A. Henry, M. Arbabi-Ghahroudi, and J. K. Scott, "Beyond phage display: non-traditional applications of the filamentous bacteriophage as a vaccine carrier, therapeutic biologic, and bioconjugation scaffold," Frontiers in Microbiology, vol. 6, no. 755, pp. 1629-1618, 2015.
7. P. H. Hofschneider and K. Mueller-Jensen, "Über infektiöse Substrukturen aus E. coli-Bakteriophagen," Zeitschrift für Naturforschung Part B, vol. 18, no. 11, pp. 922-927, 1963.
8. D. A. Marvin and H. Hoffmann-Berling, "A fibrous DNA phage (fd) and a spherical RNA phage (fr) specific for male strains of E coli," Zeitschrift für Naturforschung Part B, vol. 18, no. 11, pp. 884-893, 1963.
9. N. D. Zinder, R. C. Valentine, M. Roger, and W. Stoeckenius, "F1, a rod-shaped male-specific bacteriophage that contains DNA," Virology, vol. 20, no. 4, pp. 638-640, 1963.
10. W. O. Salivar, H. Tzagoloff, and D. Pratt, "Some physicalchemical and biological properties of the rod-shaped coliphage M13," Virology, vol. 24, no. 3, pp. 359-371, 1964.
11. C. M. Fauquet and D. Fargette, "International Committee on Taxonomy of Viruses and the 3, 142 unassigned species," Virology Journal, vol. 2, no. 1, p. 64, 2005.
12. S. Danner and J. G. Belasco, "T7 phage display: a novel genetic selection system for cloning RNA-binding proteins from cDNA libraries," Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 23, pp. 12954-12959, 2001.
13. N. Chanishvili, "Phage therapy - history from Twort and d'Herelle through Soviet experience to current approaches," Advances in Virus Research, vol. 83, pp. 3-40, 2012.
14. W. C. Summers, "Bacteriophage therapy," Annual Review of Microbiology, vol. 55, no. 3, pp. 437-451, 2001.
15. R. Bruynoghe and J. Maisin, "Essais de thérapeutique au moyen du bacteriophage," CR Society of Biology, vol. 85, pp. 1120-1121, 1921.
16. S. E. Luria, M. Delbrück, and T. F. Anderson, "Electron microscope studies of bacterial viruses," Journal of Bacteriology, vol. 46, no. 1, pp. 57-77, 1943.
17. S. E. Luria and M. Delbrück, "Mutations of bacteria from virus sensitivity to virus resistance," Genetics, vol. 28, no. 6, pp. 491-511, 1943.
18. C. L. Ventola, "The antibiotic resistance crisis: part 1: causes and threats," P t., vol. 40, no. 4, pp. 277-283, 2015.
19. J. R. Clark and J. B. March, "Bacterial viruses as human vaccines?" Expert Review of Vaccines, vol. 3, no. 4, pp. 463-476, 2004.
20. N. Clementi, E. Criscuolo, M. Castelli, and M. Clementi, "Broad-range neutralizing anti-influenza A human monoclonal antibodies: new perspectives in therapy and prophylaxis," The new Microbiologica, vol. 35, no. 4, pp. 399-406, 2012.
21. T. Menéndez, N. F. Santiago-Vispo, Y. Cruz-Leal et al., "Identification and characterization of phage-displayed peptide mimetics of Neisseria meningitidis serogroup B capsular polysaccharide," International Journal of Medical Microbiology, vol. 301, no. 1, pp. 16-25, 2011.
22. G. Sautto, N. Mancini, R. A. Diotti, L. Solforosi, M. Clementi, and R. Burioni, "Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference," Antiviral Research, vol. 96, no. 1, pp. 82-89, 2012.
23. H. M. Mir, A. Birerdinc, and Z. M. Younossi, "Monoclonal and polyclonal antibodies against the HCV envelope proteins," Clinics in Liver Disease, vol. 13, no. 3, pp. 477-486, 2009.
24. R. A. Diotti, N. Mancini, N. Clementi et al., "Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy," Antiviral Research, vol. 108, no. 1, pp. 94-103, 2014.
25. R. A. Williamson, R. Burioni, P. P. Sanna, L. J. Partridge, C. F. Barbas, and D. R. Burton, "Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries," Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 9, pp. 4141-4145, 1993.
26. J. Thompson, T. Pope, J. S. Tung et al., "Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity," Journal of Molecular Biology, vol. 256, no. 1, pp. 77-88, 1996.
27. J. Cao, Y. Sun, T. Berglindh et al., "Helicobacter pyloriantigen-binding fragments expressed on the filamentous M13 phage prevent bacterial growth," Biochimica et Biophysica Acta, vol. 1474, no. 1, pp. 107-113, 2000.
28. R. Burioni, R. A. Williamson, P. P. Sanna, F. E. Bloom, and D. R. Burton, "Recombinant human Fab to glycoprotein D neutralizes infectivity and prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in vitro," Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 1, pp. 355-359, 1994.
29. C. C. Lee, L. L. Lin, W. E. Chan, T.-P. Ko, J. S. Lai, and A. H. J. Wang, "Structural basis for the antibody neutralization of Herpes simplex virus," Acta Crystallographica. Section D, Biological Crystallography, vol. 69, no. Part 10, pp. 1935-1945, 2013.
30. E. A. Lindquist, J. D. Marks, B. J. Kleba, and R. S. Stephens, "Phage-display antibody detection of Chlamydia trachomatis-associated antigens," Microbiology, vol. 148, no. Part 2, pp. 443-451, 2002.
31. G. C. Paoli, C.Y. Chen, and J. D. Brewster, "Single-chain Fv antibody with specificity for Listeria monocytogenes," Journal of Immunological Methods, vol. 289, no. 1-2, pp. 147-155, 2004.
32. Y. Zhu, B. Ho, and J. L. Ding, "Sequence and structural diversity in endotoxin-binding dodecapeptides," Biochimica et Biophysica Acta, vol. 1611, no. 1-2, pp. 234-242, 2003.
33. X.L. Zhao, J. Yin, W.Q. Chen, M. Jiang, G. Yang, and Z.H. Yang, "Generation and characterization of human monoclonal antibodies to G5, a linear neutralization epitope on glycoprotein of rabies virus, by phage display technology," Microbiology and Immunology, vol. 52, no. 2, pp. 89-93, 2008.
34. N. Sabarth, R. Hurvitz, M. Schmidt et al., "Identification of helicobacter pylori surface proteins by selective proteinase K digestion and antibody phage display," Journal of Microbiological Methods, vol. 62, no. 3, pp. 345-349, 2005.
35. H. Wu, D. S. Pfarr, S. Johnson et al., "Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract," Journal of Molecular Biology, vol. 368, no. 3, pp. 652-665, 2007.
36. S. Ran, J. He, X. Huang, M. Soares, D. Scothorn, and P. E. Thorpe, "Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice," Clinical Cancer Research, vol. 11, no. 4, pp. 1551-1562, 2005.
37. T.-S. Migone, G. M. Subramanian, J. Zhong et al., "Raxibacumab for the treatment of inhalational anthrax," The New England Journal of Medicine, vol. 361, no. 2, pp. 135-144, 2009.
38. R. Odegrip, D. Coomber, B. Eldridge et al., "CIS display: in vitro selection of peptides from libraries of protein-DNA complexes," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 9, pp. 2806-2810, 2004.
39. J. Steel, "New strategies for the development of H5N1 subtype influenza vaccines: progress and challenges," BioDrugs, vol. 25, no. 5, pp. 285-298, 2011.
40. C. Johnston, D. M. Koelle, and A. Wald, "HSV-2: in pursuit of a vaccine," The Journal of Clinical Investigation, vol. 121, no. 12, pp. 4600-4609, 2011.
41. J. R. Danko, C. G. Beckett, and K. R. Porter, "Development of dengue DNA vaccines," Vaccine, vol. 29, no. 42, pp. 7261-7266, 2011.
42. P. J. Klasse and Q. J. Sattentau, "Occupancy and mechanism in antibody-mediated neutralization of animal viruses," The Journal of General Virology, vol. 83, no. Part 9, pp. 2091-2108, 2002.
43. R. Dulbecco, M. Vogt, and A. G. Strickland, "A study of the basic aspects of neutralization of two animal viruses, western equine encephalitis virus and poliomyelitis virus," Virology, vol. 2, no. 2, pp. 162-205, 1956.
44. A. Takada and Y. Kawaoka, "Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications," Reviews in Medical Virology, vol. 13, no. 6, pp. 387-398, 2003.
45. J. P. O'Rourke, D. S. Peabody, and B. Chackerian, "Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platform," Current Opinion in Virology, vol. 11, pp. 76-82, 2015.
46. M. Castelli, F. Cappelletti, R. A. Diotti et al., "Peptide-based vaccinology: experimental and computational approaches to target hypervariable viruses through the fine characterization of protective epitopes recognized by monoclonal antibodies and the identification of T-cell-activating peptides," Clinical and Developmental Immunology, vol. 2013, Article ID 521231, pp. 1-12, 2013.
47. P. Vukovic, K. Chen, X. Qin Liu et al., "Single-chain antibodies produced by phage display against the C-terminal 19 kDa region of merozoite surface protein-1 of Plasmodium yoelii reduce parasite growth following challenge," Vaccine, vol. 20, no. 21-22, pp. 2826-2835, 2002.
48. F. Bugli, N. Mancini, C. Y. Kang et al., "Mapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display libraries," Journal of Virology, vol. 75, no. 20, pp. 9986-9990, 2001.
49. H. Hashemi, T. Bamdad, A. Jamali, S. Pouyanfard, and M. G. Mohammadi, "Evaluation of humoral and cellular immune responses against HSV-1 using genetic immunization by filamentous phage particles: a comparative approach to conventional DNA vaccine," Journal of Virological Methods, vol. 163, no. 2, pp. 440-444, 2010.
50. L. Aghebati-Maleki, B. Bakhshinejad, B. Baradaran et al., "Phage display as a promising approach for vaccine development," Journal of Biomedical Science, vol. 23, p. 66, 2016.
51. P. Tao, M. Mahalingam, M. L. Kirtley et al., "Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines," PLoS Pathogens, vol. 9, no. 7, article e1003495, 2013.
52. T. Sathaliyawala, M. Rao, D. M. Maclean, D. L. Birx, C. R. Alving, and V. B. Rao, "Assembly of human immunodeficiency virus (HIV) antigens on bacteriophage T4: a novel in vitro approach to construct multicomponent HIV vaccines," Journal of Virology, vol. 80, no. 15, pp. 7688-7698, 2006.
53. H. Hashemi, S. Pouyanfard, M. Bandehpour et al., "Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge," PloS One, vol. 7, no. 9, article e45765, 2012.
54. J. R. Clark and J. B. March, "Bacteriophage-mediated nucleic acid immunisation," FEMS Immunology and Medical Microbiology, vol. 40, no. 1, pp. 21-26, 2004.
55. C. Ou, D. Tian, Y. Ling et al., "Evaluation of an ompA-based phage-mediated DNA vaccine against Chlamydia abortus in piglets," International Immunopharmacology, vol. 16, no. 4, pp. 505-510, 2013.
56. S. Latz, A. Wahida, A. Arif et al., "Preliminary survey of local bacteriophages with lytic activity against multi-drug resistant bacteria," Journal of Basic Microbiology, vol. 56, no. 10, pp. 1117-1123, 2016.
57. D. D. Rhoads, R. D. Wolcott, M. A. Kuskowski, B. M. Wolcott, L. S. Ward, and A. Sulakvelidze, "Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial," Journal of Wound Care, vol. 18, no. 6, pp. 237-238, 2013, 2013.
58. S. A. Sarker, S. Sultana, G. Reuteler et al., "Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh," eBioMedicine, vol. 4, pp. 124-137, 2016.
59. H. Oliveira, S. Sillankorva, M. Merabishvili, L. D. Kluskens, and J. Azeredo, "Unexploited opportunities for phage therapy," Frontiers in Pharmacology, vol. 6, p. 180, 2015.
60. A. S. Nilsson, "Phage therapy - constraints and possibilities," Upsala Journal of Medical Sciences, vol. 119, no. 2, pp. 192-198, 2014.
61. K. Hodyra-Stefaniak, P. Miernikiewicz, J. Drapała et al., "Mammalian host-versus-phage immune response determines phage fate in vivo," Scientific Reports, vol. 5, article 14802, p. 14802, 2015.
62. E. M. Ryan, S. P. Gorman, R. F. Donnelly, and B. F. Gilmore, "Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy," The Journal of Pharmacy and Pharmacology, vol. 63, no. 10, pp. 1253-1264, 2011.
63. Z. Drulis-Kawa, G. Majkowska-Skrobek, and B. Maciejewska, "Bacteriophages and phage-derived proteins - application approaches," Current Medicinal Chemistry, vol. 22, no. 14, pp. 1757-1773, 2015.
64. H.-C. Flemming, J. Wingender, U. Szewzyk, P. Steinberg, S. A. Rice, and S. Kjelleberg, "Biofilms: an emergent form of bacterial life," Nature Reviews. Microbiology, vol. 14, no. 9, pp. 563-575, 2016.
65. T. Harada, "Special bacterial polysaccharides and polysaccharases," Biochemical Society Symposium, vol. 48, pp. 97-116, 1983.
66. R. Dubos and O. T. Avery, "Decomposition of the capsular polysaccharide of pneumococcus type III by a bacterial enzyme," The Journal of Experimental Medicine, vol. 54, no. 1, pp. 51-71, 1931.
67. K. Goodner and R. Dubos, "Studies on the quantitative action of a specific enzyme in type III pneumococcus dermal infection in rabbits," The Journal of Experimental Medicine, vol. 56, no. 4, pp. 521-530, 1932.
68. T. Francis, E. E. Terrell, R. Dubos, and O. T. Avery, "Experimental type III pneumococcus pneumonia in monkeys: II. Treatment with an enzyme which decomposes the specific capsular polysaccharide of pneumococcus type III," The Journal of Experimental Medicine, vol. 59, no. 5, pp. 641-667, 1934.
69. N. Mushtaq, M. B. Redpath, J. P. Luzio, and P. W. Taylor, "Treatment of experimental Escherichia coli infection with recombinant bacteriophage-derived capsule depolymerase," The Journal of Antimicrobial Chemotherapy, vol. 56, no. 1, pp. 160-165, 2005.
70. A. Scorpio, D. J. Chabot, W. A. Day et al., "Poly-gamma-glutamate capsule-degrading enzyme treatment enhances phagocytosis and killing of encapsulated bacillus anthracis," Antimicrobial Agents and Chemotherapy, vol. 51, no. 1, pp. 215-222, 2007.
71. A. Scorpio, S. A. Tobery, W. J. Ribot, and A. M. Friedlander, "Treatment of experimental anthrax with recombinant capsule depolymerase," Antimicrobial Agents and Chemotherapy, vol. 52, no. 3, pp. 1014-1020, 2008.
72. A. Zelmer, M. J. Martin, O. Gundogdu et al., "Administration of capsule-selective endosialidase E minimizes upregulation of organ gene expression induced by experimental systemic infection with Escherichia coli K1," Microbiology, vol. 156, no. Part 7, pp. 2205-2215, 2010, (Reading, Engl.).
73. P. M. Bales, E. M. Renke, S. L. May, Y. Shen, and D. C. Nelson, "Purification and characterization of biofilmassociated EPS exopolysaccharides from ESKAPE organisms and other pathogens," PloS One, vol. 8, no. 6, article e67950, 2013.
74. A. Cornelissen, P.-J. Ceyssens, J. T'Syen et al., "The T7-related Pseudomonas putida phage φ15 displays virion-associated biofilm degradation properties," PloS One, vol. 6, no. 4, article e18597, 2011.
75. V. Verma, K. Harjai, and S. Chhibber, "Structural changes induced by a lytic bacteriophage make ciprofloxacin effective against older biofilm of Klebsiella pneumoniae," Biofouling, vol. 26, no. 6, pp. 729-737, 2010.
76. T. K. Lu and J. J. Collins, "Dispersing biofilms with engineered enzymatic bacteriophage," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 27, pp. 11197-11202, 2007.
77. K. Tait, L. C. Skillman, and I. W. Sutherland, "The efficacy of bacteriophage as a method of biofilm eradication," Biofouling, vol. 18, no. 4, pp. 305-311, 2010.
78. G. W. Hanlon, S. P. Denyer, C. J. Olliff, and L. J. Ibrahim, "Reduction in exopolysaccharide viscosity as an aid to bacteriophage penetration through Pseudomonas aeruginosa biofilms," Applied and Environmental Microbiology, vol. 67, no. 6, pp. 2746-2753, 2001.
79. K. A. Hughes, I. W. Sutherland, and M. V. Jones, "Biofilm susceptibility to bacteriophage attack: the role of phageborne polysaccharide depolymerase," Microbiology, vol. 144, no. Part 11, pp. 3039-3047, 1998.
80. L. C. Skillman, I. W. Sutherland, and M. V. Jones, "The role of exopolysaccharides in dual species biofilm development," Journal of Applied Microbiology, vol. 85, Supplement 1, pp. 13S-18S, 1998.
81. R. Young, "Phage lysis: three steps, three choices, one outcome," Journal of Microbiology, vol. 52, no. 3, pp. 243-258, 2014.
82. L. Zhang, D. Li, X. Li et al., "LysGH15 kills Staphylococcus aureus without being affected by the humoral immune response or inducing inflammation," Scientific Reports, vol. 6, article 29344, 2016.
83. V. A. Fischetti, "Bacteriophage lytic enzymes: novel antiinfectives," Trends in Microbiology, vol. 13, no. 10, pp. 491-496, 2005.
84. D. Nelson, L. Loomis, and V. A. Fischetti, "Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme," Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 7, pp. 4107-4112, 2001.
85. Y. Briers and R. Lavigne, "Breaking barriers: expansion of the use of endolysins as novel antibacterials against Gram-negative bacteria," Future Microbiology, vol. 10, pp. 377-390, 2015.
86. Y. Yuan, Q. Peng, and M. Gao, "Characteristics of a broad lytic spectrum endolysin from phage BtCS33 of Bacillus thuringiensis," BMC Microbiology, vol. 12, no. 1, p. 297, 2012, 2010 10:1.
87. D. R. Roach and D. M. Donovan, "Antimicrobial bacteriophage-derived proteins and therapeutic applications," Bacteriophage., vol. 5, no. 3, article e1062590, 2015.
88. M. Schmelcher, D. M. Donovan, and M. J. Loessner, "Bacteriophage endolysins as novel antimicrobials," Future Microbiology, vol. 7, no. 10, pp. 1147-1171, 2012.
89. M. J. Loessner, K. Kramer, F. Ebel, and S. Scherer, "C-terminal domains of Listeria monocytogenes bacteriophage murein hydrolases determine specific recognition and high-affinity binding to bacterial cell wall carbohydrates," Molecular Microbiology, vol. 44, no. 2, pp. 335-349, 2002.
90. L. Callewaert, M. Walmagh, C. W. Michiels, and R. Lavigne, "Food applications of bacterial cell wall hydrolases," Current Opinion in Biotechnology, vol. 22, no. 2, pp. 164-171, 2011.
91. A. Merzlyak, Development and Characterization of Genetically Engineered M13 Bacteriophage as Tissue Engineering Materials, University of California, Berkeley with the University of California, San Francisco, CA, USA, 2009.
92. M. Walmagh, B. Boczkowska, B. Grymonprez, Y. Briers, Z. Drulis-Kawa, and R. Lavigne, "Characterization of five novel endolysins from gram-negative infecting bacteriophages," Applied Microbiology and Biotechnology, vol. 97, no. 10, pp. 4369-4375, 2013.
93. P. Lukacik, T. J. Barnard, and S. K. Buchanan, "Using a bacteriocin structure to engineer a phage lysin that targets Yersinia pestis," Biochemical Society Transactions, vol. 40, no. 6, pp. 1503-1506, 2012.
94. Y. Briers, M. Walmagh, B. Grymonprez et al., "Art-175 is a highly efficient antibacterial against multidrug-resistant strains and persisters of Pseudomonas aeruginosa," Antimicrobial Agents and Chemotherapy, vol. 58, no. 7, pp. 3774-3784, 2014.
95. M. Walmagh, Y. Briers, and Santos, dos, S.B., Azeredo, J., Lavigne, R., "Characterization of modular bacteriophage endolysins from Myoviridae phages OBP, 201φ2-1 and PVP-SE1," PloS One, vol. 7, no. 5, article e36991, 2012.
96. E. H. Freimer, R. M. Krause, and M. McCarty, "Studies of L forms and protoplasts of group A streptococci. I. Isolation, growth, and bacteriologic characteristics," The Journal of Experimental Medicine, vol. 110, no. 6, pp. 853-874, 1959.
97. R. Lood, B. Y. Winer, A. J. Pelzek et al., "Novel phage lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model," Antimicrobial Agents and Chemotherapy, vol. 59, no. 4, pp. 1983-1991, 2015.
98. R. Schuch, D. Nelson, and V. A. Fischetti, "A bacteriolytic agent that detects and kills bacillus anthracis," Nature, vol. 418, no. 6900, pp. 884-889, 2002.
99. P. Yoong, R. Schuch, D. Nelson, and V. A. Fischetti, "PlyPH, a bacteriolytic enzyme with a broad pH range of activity and lytic action against Bacillus anthracis," Journal of Bacteriology, vol. 188, no. 7, pp. 2711-2714, 2006.
100. Y. Briers, M. Walmagh, V. Van Puyenbroeck et al., "Engineered endolysin-based "Artilysins" to combat multidrugresistant gram-negative pathogens," MBio, vol. 5, no. 4, e01379, p. 14, 2014.
101. M. Rashel, J. Uchiyama, T. Ujihara et al., "Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage phi MR11," The Journal of Infectious Diseases, vol. 196, no. 8, pp. 1237-1247, 2007.
102. A. Daniel, C. Euler, M. Collin, P. Chahales, K. J. Gorelick, and V. A. Fischetti, "Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillinresistant Staphylococcus aureus," Antimicrobial Agents and Chemotherapy, vol. 54, no. 4, pp. 1603-1612, 2010.
103. M. Pastagia, C. Euler, P. Chahales, J. Fuentes-Duculan, J. G. Krueger, and V. A. Fischetti, "A novel chimeric lysin shows superiority to mupirocin for skin decolonization of methicillin-resistant and-sensitive Staphylococcus aureus strains," Antimicrobial Agents and Chemotherapy, vol. 55, no. 2, pp. 738-744, 2011.
104. J. Gu, W. Xu, L. Lei et al., "LysGH15, a novel bacteriophage lysin, protects a murine bacteremia model efficiently against lethal methicillin-resistant Staphylococcus aureus infection," Journal of Clinical Microbiology, vol. 49, no. 1, pp. 111-117, 2011.
105. J. Gu, J. Zuo, L. Lei et al., "LysGH15 reduces the inflammation caused by lethal methicillin-resistant Staphylococcus aureus infection in mice," Bioengineered Bugs, vol. 2, no. 2, pp. 96-99, 2011.
106. D. B. Gilmer, J. E. Schmitz, C. W. Euler, and V. A. Fischetti, "Novel bacteriophage lysin with broad lytic activity protects against mixed infection by Streptococcus pyogenes and methicillin-resistant Staphylococcus aureus," Antimicrobial Agents and Chemotherapy, vol. 57, no. 6, pp. 2743-2750, 2013.
107. M. Schmelcher, A. M. Powell, S. C. Becker, M. J. Camp, and D. M. Donovan, "Chimeric phage lysins act synergistically with lysostaphin to kill mastitis-causing Staphylococcus aureus in murine mammary glands," Applied and Environmental Microbiology, vol. 78, no. 7, pp. 2297-2305, 2012.
108. M. Schmelcher, Y. Shen, D. C. Nelson et al., "Evolutionarily distinct bacteriophage endolysins featuring conserved peptidoglycan cleavage sites protect mice from MRSA infection," The Journal of Antimicrobial Chemotherapy, vol. 70, no. 5, pp. 1453-1465, 2015.
109. P. K. Singh, D. M. Donovan, and A. Kumar, "Intravitreal injection of the chimeric phage endolysin Ply187 protects mice from Staphylococcus aureus endophthalmitis," Antimicrobial Agents and Chemotherapy, vol. 58, no. 8, pp. 4621-4629, 2014.
110. S. Y. Jun, G. M. Jung, S. J. Yoon et al., "Antibacterial properties of a pre-formulated recombinant phage endolysin, SAL-1," International Journal of Antimicrobial Agents, vol. 41, no. 2, pp. 156-161, 2013.
111. S. Y. Jun, G. M. Jung, S. J. Yoon et al., "Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient," Antimicrobial Agents and Chemotherapy, vol. 58, no. 4, pp. 2084-2088, 2014.
112. Q. Cheng and V. A. Fischetti, "Mutagenesis of a bacteriophage lytic enzyme PlyGBS significantly increases its antibacterial activity against group B streptococci," Applied Microbiology and Biotechnology, vol. 74, no. 6, pp. 1284-1291, 2007.
113. Q. Cheng, D. Nelson, S. Zhu, and V. A. Fischetti, "Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme," Antimicrobial Agents and Chemotherapy, vol. 49, no. 1, pp. 111-117, 2005.
114. F. Oechslin, J. Daraspe, M. Giddey, P. Moreillon, and G. Resch, "In vitro characterization of PlySK1249, a novel phage lysin, and assessment of its antibacterial activity in a mouse model of Streptococcus agalactiae bacteremia," Antimicrobial Agents and Chemotherapy, vol. 57, no. 12, pp. 6276-6283, 2013.
115. J. M. Entenza, J. M. Loeffler, D. Grandgirard, V. A. Fischetti, and P. Moreillon, "Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats," Antimicrobial Agents and Chemotherapy, vol. 49, no. 11, pp. 4789-4792, 2005.
116. I. Pérez-Dorado, N. E. Campillo, B. Monterroso et al., "Elucidation of the molecular recognition of bacterial cell wall by modular pneumococcal phage endolysin CPL-1," The Journal of Biological Chemistry, vol. 282, no. 34, pp. 24990-24999, 2007.
117. R. Diez-Martinez, H. D. De Paz, E. García-Fernández et al., "A novel chimeric phage lysin with high in vitro and in vivo bactericidal activity against Streptococcus pneumoniae," The Journal of Antimicrobial Chemotherapy, vol. 70, no. 6, pp. 1763-1773, 2015.
118. R. Diez-Martinez, H. D. De Paz, H. de Paz et al., "Improving the lethal effect of cpl-7, a pneumococcal phage lysozyme with broad bactericidal activity, by inverting the net charge of its cell wall-binding module," Antimicrobial Agents and Chemotherapy, vol. 57, no. 11, pp. 5355-5365, 2013.
119. J. A. McCullers, A. Karlström, A. R. Iverson, J. M. Loeffler, and V. A. Fischetti, "Novel strategy to prevent otitis media caused by colonizing Streptococcus pneumoniae," PLoS Pathogens, vol. 3, article e28, no. 3, 2007.
120. J. M. Loeffler and V. A. Fischetti, "Synergistic lethal effect of a combination of phage lytic enzymes with different activities on penicillin-sensitive and-resistant Streptococcus pneumoniae strains," Antimicrobial Agents and Chemotherapy, vol. 47, no. 1, pp. 375-377, 2003.
121. C. J. Cooper, M. Khan Mirzaei, and A. S. Nilsson, "Adapting drug approval pathways for bacteriophage-based therapeutics," Frontiers in Microbiology, vol. 7, article 1209, p. 1209, 2016.
122. A. Nakonieczna, C. J. Cooper, and R. Gryko, "Bacteriophages and bacteriophage-derived endolysins as potential therapeutics to combat gram-positive spore forming bacteria," Journal of Applied Microbiology, vol. 119, no. 3, pp. 620-631, 2015.
123. T. Rajesh, T. Anthony, S. Saranya, P. L. Pushpam, and P. Gunasekaran, "Functional characterization of a new holinlike antibacterial protein coding gene tmp1 from goat skin surface metagenome," Applied Microbiology and Biotechnology, vol. 89, no. 4, pp. 1061-1073, 2011.
124. J. G. Kenny, S. McGrath, G. F. Fitzgerald, and D. van Sinderen, "Bacteriophage Tuc2009 encodes a tail-associated cell wall-degrading activity," Journal of Bacteriology, vol. 186, no. 11, pp. 3480-3491, 2004.
125. A. A. Vipra, S. N. Desai, P. Roy et al., "Antistaphylococcal activity of bacteriophage derived chimeric protein P128," BMC Microbiology, vol. 12, no. 1, p. 41, 2012, 2010 10.
126. T. Pang, T. C. Fleming, K. Pogliano, and R. Young, "Visualization of pinholin lesions in vivo," Proceedings of the National Academy of Sciences, vol. 110, no. 22, pp. E2054-E2063, 2013.
127. Y. Shi, N. Li, Y. Yan et al., "Combined antibacterial activity of phage lytic proteins holin and lysin from Streptococcus suis bacteriophage SMP," Current Microbiology, vol. 65, no. 1, pp. 28-34, 2012.
128. N. D. Olson and J. B. Morrow, "DNA extract characterization process for microbial detection methods development and validation," BMC Research Notes, vol. 5, no. 1, p. 668, 2012.
129. M. J. Loessner, C. E. Rees, G. S. Stewart, and S. Scherer, "Construction of luciferase reporter bacteriophage A511:luxAB for rapid and sensitive detection of viable Listeria cells," Applied and Environmental Microbiology, vol. 62, no. 4, pp. 1133-1140, 1996.
130. D. A. Schofield, I. J. Molineux, and C. Westwater, ""Bioluminescent" reporter phage for the detection of category a bacterial pathogens," Journal of Visualized Experiments, vol. article e2740, no. 53, 2011.
131. R. Awais, H. Fukudomi, K. Miyanaga, H. Unno, and Y. Tanji, "A recombinant bacteriophage-based assay for the discriminative detection of culturable and viable but nonculturable Escherichia coli O157:H7," Biotechnology Progress, vol. 22, no. 3, pp. 853-859, 2006.
132. H. Anany, W. Chen, R. Pelton, and M. W. Griffiths, "Biocontrol of Listeria monocytogenes and Escherichia coli O157:H7 in meat by using phages immobilized on modified cellulose membranes," Applied and Environmental Microbiology, vol. 77, no. 18, pp. 6379-6387, 2011.
133. P. Bardy, R. Pantůček, M. Benešík, and J. Doškař, "Genetically modified bacteriophages in applied microbiology," Journal of Applied Microbiology, vol. 121, no. 3, pp. 618-633, 2016.
134. H. Albert, A. Heydenrych, R. Mole, A. Trollip, and L. Blumberg, "Evaluation of FASTPlaqueTB-RIF, a rapid, manual test for the determination of rifampicin resistance from Mycobacterium tuberculosis cultures," The International Journal of Tuberculosis and Lung Disease, vol. 5, no. 10, pp. 906-911, 2001.
135. M. Smietana, W. J. Bock, P. Mikulic, A. Ng, R. Chinnappan, and M. Zourob, "Detection of bacteria using bacteriophages as recognition elements immobilized on long-period fiber gratings," Optics Express, vol. 19, no. 9, pp. 7971-7978, 2011.
136. H. Traore, S. Ogwang, K. Mallard et al., "Low-cost rapid detection of rifampicin resistant tuberculosis using bacteriophage in Kampala, Uganda," Annals of Clinical Microbiology and Antimicrobials, vol. 6, no. 1, p. 1, 2007.
137. F. C. Tenover, R. Arbeit, G. Archer et al., "Comparison of traditional and molecular methods of typing isolates of Staphylococcus aureus," Journal of Clinical Microbiology, vol. 32, no. 2, pp. 407-415, 1994.
138. A. van Belkum and W. M. Dunne, "Next-generation antimicrobial susceptibility testing," Journal of Clinical Microbiology, vol. 51, no. 7, pp. 2018-2024, 2013.
139. S. Hagens, T. de Wouters, P. Vollenweider, and M. J. Loessner, "Reporter bacteriophage A511:celB transduces a hyperthermostable glycosidase from Pyrococcus furiosus for rapid and simple detection of viable Listeria cells," Bacteriophage, vol. 1, no. 3, pp. 143-151, 2011.
140. K. V. Sullivan, N. N. Turner, S. S. Roundtree, and K. L. McGowan, "Rapid detection of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible Staphylococcus aureus (MSSA) using the KeyPath MRSA/MSSA blood culture test and the BacT/ALERT system in a pediatric population," Archives of Pathology & Laboratory Medicine, vol. 137, no. 8, pp. 1103-1105, 2013.